Li Zhou

Years Active: 2021-2023
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Xiao-Shuai Zhang, Robert Peter Gale, Bingcheng Liu, Jian Huang, Yanli Zhang, Xin Du, Jian-Yu Weng, Weiming Li, Na Xu, Xiaoli Liu, Chunyan Chen, Hai Lin, Guohui Li, Rong Liang, Zhuogang Liu, Xiaodong Wang, Yanqing Zhang, Yanqiu Han, Chunshui Liu, Jian-da Hu, Lie Lin, Wei Yang, Zhenfang Liu, Li Meng, Chuanqing Tu, Caifeng Zheng, Zeping Zhou, Yanliang Bai, Huiying Qiu, Suning Chen, Fei Li, Jianxin Guo, Zelin Liu, Hui Sun, Li Zhou, Ru Feng, Xiuli Sun, Xiao-Jun Huang, Qian Jiang
Validation of the imatinib-therapy failure model. Leukemia (2023)
Hu Lei, Han-Zhang Xu, Hui-Zhuang Shan, Meng Liu, Ying Lu, Zhi-Xiao Fang, Jin Jin, Bo Jing, Xin-Hua Xiao, Shen-Meng Gao, Feng-Hou Gao, Li Xia, Li Yang, Li-Gen Liu, Wei-Wei Wang, Chuan-Xu Liu, Yin Tong, Yun-Zhao Wu, Jun-Ke Zheng, Guo-Qiang Chen, Li Zhou, Ying-Li Wu
Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia. Nature communications 12 (1) (2021)

Li Zhou.css-eqlu8i{font-size:small;padding-left:4px;}